造血干细胞移植术后巨细胞病毒肺炎的现状与进展  

Current status and advances of cytomegalovirus pneumonia after hematopoietic stem cell transplantation

作　　者：郑焱华 任芮林 李晓帆 ZHENG Yan-hua;REN Rui-lin;LI Xiao-fan(Fujian Hematology Institute,Fuzhou 350000,China;Department of Hematology,The First Hospital of China Medical University,Shenyang 110000,China;Department of Hematology,Fujian Medical University Union Hospital,Fuzhou 350000,China;Fujian Medical University,Fuzhou 350000,China)

机构地区：[1]福建省血液病研究所,福建福州350000 [2]中国医科大学附属第一医院血液科,辽宁沈阳110000 [3]福建医科大学附属协和医院血液科,福建福州350000 [4]福建医科大学,福建福州350000

出　　处：《中国感染控制杂志》2024年第1期126-132,共7页Chinese Journal of Infection Control

基　　金：福建省自然科学基金项目(2021J01782);福建省卫健委科技计划项目(2021GGA018)。

摘　　要：巨细胞病毒(CMV)肺炎是常见的造血干细胞移植并发症之一,也是导致患者死亡的重要原因。因CMV肺炎预后高度不良,需行必要的干预手段以防止CMV再激活进展至CMV肺炎。目前临床上主要依据抢先治疗策略用药,其用药时机取决于早期诊断的时效性,而CMV肺炎的早期诊断在临床上现有可行方法学及手段较为有限,诊断金标准的操作具有一定创伤性和侵入性,且检出时效较差。本综述总结造血干细胞移植术后CMV肺炎的诊断及药物预防治疗的临床现状与进展,探究未来可能的发展方向与趋势。Cytomegalovirus(CMV)pneumonia is one of the common complications of hematopoietic stem cell transplantation,and is also a significant cause leading to patient death.Due to the poor prognosis of CMV pneumonia,intervention measures are necessary to prevent CMV reactivation and progress to CMV pneumonia.At present,clinical medication mainly relies on preemptive treatment strategies,and the timing of medication depends on the timeliness of early diagnosis.However,feasible methodology and measures for the early diagnosis of CMV pneumonia in clinical practice are relatively limited.Meanwhile the diagnostic gold standard operation is invasive,causing trauma to a certain degree,and the detection timeliness is poor.This review summarizes the clinical status and advances in the diagnosis and drug prophylactic treatment of CMV pneumonia after hematopoietic stem cell transplantation,and explores possible development directions and trends in the future.

关 键 词：造血干细胞移植 巨细胞病毒 肺炎 影像组学 预防治疗 

分 类 号：R563.1[医药卫生—呼吸系统]